{
    "nct_id": "NCT03941769",
    "official_title": "A Phase I/II Study of Recombinant Human Interleukin-7 to Promote T-Cell Recovery After Haploidentical and Cord Blood Stem Cell Transplantation",
    "inclusion_criteria": "* English and non-English speaking patients are eligible.\n* Patient post a cord blood transplant (CBT) or haplo-SCT, with matched unrelated donors (MUDs), both peripheral blood (PB) and marrow sources with documented absolute neutrophil engraftment\n* Patients with documented engraftment but require granulocyte-colony stimulating factor (G-CSF) to treat myelosuppression induced by drugs used to treat or prevent infection are eligible\n* Karnofsky performance status (KPS) > 60%\n* Absence of dyspnea or hypoxia (< 90% of saturation by pulse oximetry on room air)\n* Bilirubin =< 1.5 x upper limit of normal (ULN)\n* Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and/or alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x ULN\n* Prothrombin time (PT)/partial prothrombin time (PTT) < 1.5 x ULN\n* Calculated creatinine clearance > 60 mL/min/1.73 m^2\n* Diagnosis of acute myeloid leukemia; myelodysplastic syndrome; chronic myeloid leukemia; myelofibrosis or myeloproliferative disease\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Pregnant or nursing\n* History of lymphoid malignancy (including Hodgkin disease, non-Hodgkin lymphoma, acute lymphoblastic leukemia and chronic lymphocytic leukemia) or acute biphenotypic leukemia\n* Patients with acute GVHD > grade 2 at any time during the post-transplant course\n* Ongoing immunosuppressive therapy for the treatment of GVHD. Patients receiving GVHD prophylaxis will be allowed on this study\n* History of Epstein-Barr virus (EBV) associated lymphoproliferation\n* Active uncontrolled viral, bacterial or fungal infection\n* History of autoimmune disease\n* Receiving systemic corticosteroid therapy, budesonide is allowed\n* Uncontrolled hypertension\n* Corrected QT (QTc) prolongation (QTc > 470 ms) or prior history of significant arrhythmia or electrocardiogram (ECG) abnormalities\n* Active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements\n* Patients with cognitive impairments and/or any past or current psychiatric illness that, in the opinion of the investigator, would interfere with adherence to study requirements or the ability and willingness to give written informed consent",
    "miscellaneous_criteria": ""
}